NO20073033L - Cytotoksiske midler innbefattende nye taksaner - Google Patents

Cytotoksiske midler innbefattende nye taksaner

Info

Publication number
NO20073033L
NO20073033L NO20073033A NO20073033A NO20073033L NO 20073033 L NO20073033 L NO 20073033L NO 20073033 A NO20073033 A NO 20073033A NO 20073033 A NO20073033 A NO 20073033A NO 20073033 L NO20073033 L NO 20073033L
Authority
NO
Norway
Prior art keywords
cytotoxic agents
taxanes
agents including
including new
new taxanes
Prior art date
Application number
NO20073033A
Other languages
English (en)
Norwegian (no)
Inventor
Alain Commercon
Michael Miller
Ravi V J Chari
Erkan Baloglu
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073033(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20073033L publication Critical patent/NO20073033L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20073033A 2004-12-07 2007-06-14 Cytotoksiske midler innbefattende nye taksaner NO20073033L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04292898A EP1669358A1 (fr) 2004-12-07 2004-12-07 Agents cytotoxiques comprenant des nouveau taxanes
PCT/EP2005/014177 WO2006061258A2 (fr) 2004-12-07 2005-12-02 Agents cytotoxiques comprenant de nouveaux taxanes

Publications (1)

Publication Number Publication Date
NO20073033L true NO20073033L (no) 2007-08-28

Family

ID=34931583

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073033A NO20073033L (no) 2004-12-07 2007-06-14 Cytotoksiske midler innbefattende nye taksaner

Country Status (22)

Country Link
US (1) US7667054B2 (fr)
EP (2) EP1669358A1 (fr)
JP (1) JP2008523019A (fr)
KR (1) KR20070085781A (fr)
CN (1) CN101094857A (fr)
AR (1) AR054100A1 (fr)
AU (1) AU2005313444B2 (fr)
BR (1) BRPI0518869A2 (fr)
CA (1) CA2588587A1 (fr)
DO (1) DOP2005000248A (fr)
EA (1) EA012625B1 (fr)
IL (1) IL183404A0 (fr)
MA (1) MA29103B1 (fr)
MX (1) MX2007006765A (fr)
MY (1) MY144632A (fr)
NO (1) NO20073033L (fr)
NZ (1) NZ555406A (fr)
PE (2) PE20110001A1 (fr)
TW (1) TW200637836A (fr)
UY (1) UY29249A1 (fr)
WO (1) WO2006061258A2 (fr)
ZA (1) ZA200704790B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
AU2002311919B8 (en) 2001-05-11 2007-03-22 Ludwig Institute For Cancer Research Ltd Specific binding proteins and uses thereof
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
CA2680854C (fr) * 2007-03-15 2017-02-14 Ludwig Institute For Cancer Research Procede de traitement utilisant des anticorps d'egfr et des inhibiteurs de src, et formulations en rapport
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
CN101851231A (zh) * 2010-05-27 2010-10-06 东北林业大学 一种多西紫杉醇新衍生物的合成方法及其在制备抗肿瘤药物中的应用
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
ES2781523T3 (es) 2012-07-12 2020-09-02 Hangzhou Dac Biotech Co Ltd Conjugados de moléculas de unión celular con agentes citotóxicos
CA2891280C (fr) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Lieurs hydrophiles et leurs utilisations pour la conjugaison de medicaments a des molecules se liant aux cellules
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
CN104693156A (zh) * 2014-10-22 2015-06-10 上海大学 9,10-二羟基-1-去氧紫杉醇类似物及其制备方法
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR20220150408A (ko) 2016-11-14 2022-11-10 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
EP4426727A2 (fr) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique d'un anticorps

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2388063C (fr) * 1999-11-24 2010-06-08 Immunogen, Inc. Agents cytotoxiques comprenant des taxanes et leur utilisation therapeutique
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
BR0313197A (pt) * 2002-08-02 2005-08-09 Immunogen Inc Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico

Also Published As

Publication number Publication date
KR20070085781A (ko) 2007-08-27
WO2006061258A2 (fr) 2006-06-15
BRPI0518869A2 (pt) 2008-12-16
UY29249A1 (es) 2006-06-30
DOP2005000248A (es) 2007-02-15
MX2007006765A (es) 2007-08-16
AR054100A1 (es) 2007-06-06
AU2005313444A1 (en) 2006-06-15
PE20061060A1 (es) 2006-11-14
US7667054B2 (en) 2010-02-23
EP1824858A2 (fr) 2007-08-29
MY144632A (en) 2011-10-14
IL183404A0 (en) 2007-10-31
EA012625B1 (ru) 2009-10-30
JP2008523019A (ja) 2008-07-03
CA2588587A1 (fr) 2006-06-15
CN101094857A (zh) 2007-12-26
US20060178427A1 (en) 2006-08-10
EA200701251A1 (ru) 2007-12-28
AU2005313444B2 (en) 2011-11-10
PE20110001A1 (es) 2011-01-21
ZA200704790B (en) 2008-08-27
WO2006061258A3 (fr) 2006-09-28
NZ555406A (en) 2011-02-25
EP1669358A1 (fr) 2006-06-14
MA29103B1 (fr) 2007-12-03
TW200637836A (en) 2006-11-01

Similar Documents

Publication Publication Date Title
NO20073033L (no) Cytotoksiske midler innbefattende nye taksaner
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
NO20066050L (no) Substituerte indazoler, sammensetninger inneholdende disse samt fremstilling og anvendelse derav
MY157715A (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
CL2008001197A1 (es) Compuestos derivados de amidas sustituidas, moduladoras de la actividad de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome metabolico, resistencia a la insulina, dislipidemia, entre otras.
NO20073068L (no) Stereoisomere anrikete 3-aminokarbonylbisykloheptenpyrimidindiaminforindelser og deres anvendelse
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200870019A1 (ru) Лактамовые соединения и способы их применения
ECSP077299A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos
ATE448777T1 (de) Mittel für die transdermale verabreichung von nikotin
ATE482209T1 (de) Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität
UY31484A1 (es) Piperidinas heteroaril-sustituidas
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
MX2009004883A (es) Piridil sulfoximinas multi-substituidas y su uso como insecticidas.
NO20084850L (no) MGLUR5 modulatorer I
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20090305L (no) Cyklosporin formuleringer
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20081084L (no) Arylpyridiner og fremgangsmater for deres anvendelse
NO20080158L (no) Oyedraper som inneholder roflumilast
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
BRPI0607379A2 (pt) métodos de usar como analgésicos 1-benzil-1-hidroxi-2,3-diamino-propil aminas, amidas de ácido 3-benzil-3-hidroxi-2-amino-propiÈnico e compostos relacionados
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application